Theresa Matkovits
2022
In 2022, Theresa Matkovits earned a total compensation of $850.2K as Chief Development Officer at Matinas BioPharma Holdings, a 36% decrease compared to previous year.
Compensation breakdown
| Bonus | $189,000 |
|---|---|
| Option Awards | $249,179 |
| Salary | $412,000 |
| Total | $850,179 |
Matkovits received $412K in salary, accounting for 48% of the total pay in 2022.
Matkovits also received $189K in bonus and $249.2K in option awards.
Rankings
In 2022, Theresa Matkovits' compensation ranked 3,315th out of 5,534 executives tracked by ExecPay. In other words, Matkovits earned more than 40.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,315 out of 5,534 | 40th |
Division Manufacturing | 1,866 out of 3,000 | 38th |
Major group Chemicals And Allied Products | 883 out of 1,350 | 35th |
Industry group Drugs | 825 out of 1,253 | 34th |
Industry Pharmaceutical Preparations | 598 out of 907 | 34th |
Source: SEC filing on September 19, 2023.
Matkovits' colleagues
We found two more compensation records of executives who worked with Theresa Matkovits at Matinas BioPharma Holdings in 2022.
News
Matinas BioPharma Holdings CEO Jerome Jabbour's 2022 pay falls 55% to $1.7M
September 19, 2023
Matinas BioPharma Holdings CEO Jerome Jabbour's 2021 pay jumps 26% to $3.7M
September 22, 2022
Matinas BioPharma Holdings CEO Jerome Jabbour's 2019 pay rises 6% to $1.3M
October 1, 2020
Matinas BioPharma Holdings CEO Jerome Jabbour's 2018 pay slips 1% to $1.3M
September 24, 2019